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Human cytomegalovirus (HCMV) strains that have been passaged
in vitro rapidly acquire mutations that impact viral growth. These
laboratory-adapted strains of HCMV generally exhibit restricted
tropism, produce high levels of cell-free virus and develop sus-
ceptibility to natural killer cells. To permit experimentation with
a virus that retained the phenotype of clinical virus, we recon-
structed a wild-type (wt) HCMV genome using bacterial artiﬁcial
chromosome technology. Like clinical virus, this genome proved
to be unstable in cell culture, however propagation of intact virus
was achieved by placing the RL13 and UL128 genes under condi-
tional expression. In this study, we show that wt-HCMV produces
extremely low titers of cell-free virus but can efﬁc ently infect
ﬁbroblasts, epithelial, monocyte-derived dendritic and Langer-
hans cells via direct cell-cell transmission. This process of cell-
cell transfer required the UL128 locus, but not the RL13 gene,
and was signiﬁcantly less vulnerable to the disruptive effects of
interferon, cellular restriction factors and neutralizing antibodies
compared with cell-free entry. Resistance to neutralizing antibod-
ies was dependent on high-level expression of the pentameric
gH/gL/gpUL128–131A complex, a feature of wt but not passaged
strains of HCMV.
Virology | Immune evasion | herpesvirus | HCMV | cell-cell spread
Human cytomegalovirus is a major cause of morbidity and
mortality in the immunocompromised, and the leading infectious
cause of congenital malformation. As a result, a vaccine has
been designated of the highest priority. However, basic studies
of clinically relevant isolates that inform our understanding of
the disease process are limited, due to the rapid accumulation of
genetic mutations during in vitro passage of HCMV. The same
three genetic sites are reproducibly affected: the RL13 gene,
the UL128 locus (UL128L), which comprises UL128, UL30 and
UL131A, and the ∼15kb UL/b’ gene region (1). Deletions in the
UL/b’ region can affect tropism (UL148 (2)), latency (UL136 and
UL138 (3-7)) and resistance to NK cells (UL141 (8-10), UL142
(11, 12) and UL135 (13)). Disabling mutations in RL13 and
UL128L independently contribute to the release of high-titer cell-
free virus, while loss of UL128L restricts virus entry to fibroblasts
alone by preventing assembly of a pentameric glycoprotein com-
plex (gH/gL/pUL128/pUL130/pUL131A) in the virion envelope
(1, 14, 15).
The rapid selection of mutations is a major obstacle to the
propagation of genetically intact ‘clinical’ strains of HCMV, which
in turn has led to significant gaps in our understanding of the
affiliated disease processes (16). In particular, HCMV is largely
cell-associated in vivo (17), and clinical isolates exhibit a similar
phenotype in vitro (17, 18), yet most studies in the field are based
on laboratory strains that produce high titers of cell-free virus
(19). As a consequence, little is known about the fundamental
processes involved in the infectious spread of cell-associated
HCMV.
In this study, we used a system that permits in vitro experi-
mentation with a genetically complete virus that retains the cell-
associated phenotype displayed by clinical isolates of HCMV.
Our data show that cell-cell transfer differs both qualitatively
and quantitatively from cell-free infection, enabling the virus to
overcome intrinsic cellular restriction factors, interferon-induced
antiviral factors and antibody-mediated neutralization. More-
over, the ability of wild-type (wt)-HCMV to spread via the cell-
cell route below the radar of humoral immune defences can be
attributed to high-level expression of the pentameric complex.
Collectively, these findings provide new insights into the mech-
anisms that facilitate the in vivo persistence of HCMV.
RESULTS
Cell-cell spread is more efficient than cell-free infection
To recapitulate cell-cell spread of wt-HCMV in vitro, the com-
plete strain Merlin genome was captured in a bacterial artificial
chromosome (BAC) (14). The virus was then propagated in vitro
with RL13 and UL128-131A under the control of a tetracycline
repressor (tetR). This strategy prevented the acquisition of muta-
tions in culture (20). The pentameric complex and gpRL13 were
subsequently restored to virions during a single infectious cycle
in fibroblasts lacking tetR (Fig. 1A). Extremely low quantities
of cell-free virus were produced under these conditions, akin to
clinical isolates, with peak titers below 70 PFU/ml, which equates
to 1 PFU per 1,750 infected cells (Fig. 1B).
As this extremely low yield of cell-free virions would not be
sufficient to sustain the infection, we reasoned that wt-Merlin
must be transmitted via direct cell-cell spread. Initial experiments
Signiﬁcance
Strains of human cytomegalovirus (HCMV) that have been
passaged in the laboratory fail to recapitulate the phenotypic
characteristics of ex vivo isolates due to the rapid acquisi-
tion of genetic mutations. In particular, clinical viruses spread
via direct cell-cell contact, while passaged strains spread via
diffusion of cell-free virions. We developed a method that
enables in vitro propagation of genetically intact HCMV. Using
this system, we now report that cell-cell transmission of wild-
type HCMV is not only highly efﬁcient, but also enables the
virus to overcome key innate and adaptive immune defences.
These ﬁndings inform our understanding of viral persistence
and validate a new approach to experimentation that may
facilitate the design of improved prophylactic and therapeutic
interventions against HCMV.
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Fig. 1. Characterization of cell-cell infection. (A) Diagrammatic represen-
tation of the method used to grow wild-type Merlin in vitro without risk of
mutation. (B) HFFFs were infected with variants of theMerlin BAC containing
mutations in both UL128 and RL13, wt (tet-regulated) UL128, or wt (tet-
regulated) UL128 and wt (tet-regulated) RL13 (MOI = 5). Virus was titrated
from supernatants or sonicated cell preparations. Cell-released virus (CRV)
and cell-associated virus (CAV) represent the total infectivity obtained from
cells or supernatant, respectively, over the course of the experiment. (C)
HFFFs infected with Merlin expressing IE2-GFP (MOI = 5; 72 h post-infection)
were stained with DDAO, then co-cultured with either DCs or RPE-1 cells
at the indicated ratios. Samples were analyzed by ﬂow cytometry after a
further 72 h to determine the percentage of infected DCs or RPE-1 cells
(DDAO–/GFP+). Representative data are shown. (D) DCs were co-cultured
with Merlin-infected HFFFs (MOI = 5; 72 h post-infection) for the indicated
time periods. Non-adherent cells were then removed and incubated alone
prior to ﬂow cytometric analysis 72 h after the start of co-culture. In some
experiments, a transwell was placed between the DCs and HFFFs, and the
cultureswere incubated for 72 h. Alternatively, DCswere infected via the cell-
free route using virus harvested fromMerlin-infected HFFF supernatants and
incubated in isolation for 72 h. Virus lacking UL128–131A expression (UL128–)
was used in one well. Representative data are shown.
were therefore performed with a virus (hereon termed simply
‘Merlin’) lacking RL13, which complicates the production of cell-
free virus (14), to compare the different modes of infection.
Infected human fetal foreskin fibroblasts (HFFFs; Fig 1A) were
pre-stained with DDAO and mixed with uninfected cells. Sub-
sequent infection was then identified via GFP expression linked
to the viral IE-2 gene (Supplemental Fig. 1A). Both adherent
epithelial (RPE-1) and non-adherent dendritic cells (DCs) were
readily infected in these assays (Fig. 1C). Notably, the donor-
recipient cell ratio strongly influenced the efficiency of infection
in co-cultures with RPE-1 cells, while little effect was observed in
co-cultures with DCs.
To determine the kinetics of cell-cell transfer, DCs were
removed from co-culture at different time points and incubated
in isolation for 72 h (Fig. 1D). For comparison with cell-free
infection, DCs were incubated for the same length of time with
supernatant collected from infected HFFFs over a period of 72 h.
Alternatively, transwells were used to separateDCs from infected
HFFFs. In both cases, the DCs remained uninfected, indicating
that cell-cell contact is required for infection with Merlin. In
contrast, infected DCs were readily detected within 4 h of co-
culture and accumulated progressively with time. After 24 h, one
infected DC was detected for every infected HFFF, making cell-
cell transfer of Merlin > 1,750-fold more efficient than cell-free
infection. Importantly, virus lacking the pentameric complex was
unable to spread into DCs, and provided an additional control
to verify that only newly infected DCs were counted in these
analyses. To verify that GFP expression was linked to productive
Fig. 2. Cell-cell spread is resistant to neutralizing antibodies. (A,B) Cell-
free Merlin-GFP was incubated for 1 h with speciﬁc antibodies (light blue)
against gB (C23; 3.6 µg/ml) or UL130 and UL131A (a 1:50 dilution of a
50:50 mixture of polyclonal rabbit sera raised against peptides from UL130
and UL131A), Cytotect (purple) or serum from donors testing seronegative
(white) or seropositive (black) for HCMV (1:50). HFFFs (A) or ARPE-19 cells
(B) were then infected for 2 h, overlaid and incubated for 2 weeks. Infected
cells were quantiﬁed by plaque assay. Percent neutralization was calculated
relative to the negative control (no antibody). (C–E) HFFFs were infectedwith
Merlin-GFP (MOI = 5), then stained with DDAO after 72 h and incubated with
HFFFs (C), ARPE-19 cells (D) or DCs (E) in the presence of antibodies or sera as
described in (A,B). Infected cells were quantiﬁed by ﬂow cytometry 48 h after
the start of co-culture. Percent neutralization was calculated relative to the
negative control (no antibody). (F) HFFFs were infectedwithMerlin-GFP (MOI
= 5), then stained with DDAO after 72 h and incubated with HFFFs, ARPE-
19 cells or DCs in the presence of the indicated concentrations of Cytotect.
Infected cells were quantiﬁed by ﬂow cytometry 48 h after the start of co-
culture. (G) Cell-free Merlin was incubated with the indicated concentrations
of Cytotect for 30 min. HFFFs, ARPE-19 cells or DCs were then infected for 2 h.
After a further 24 h, cells were ﬁxed and stained for IE-1. Infected cells were
quantiﬁed by ﬂow cytometry. Percent neutralization was calculated relative
to the negative control (no Cytotect). (H) The concentration of Cytotect that
inhibited infection by 50% was calculated from panels F and G.
infection, GFP+ cells were first sorted to purity using flow cytom-
etry (Supplemental Fig. 1B). Subsequent imaging revealed that
the GFP signal was localized to the nucleus, consistent with de
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Fig. 3. Levels of the pentameric complex correlate with resistance to
neutralizing antibodies. (A) ARPE-19 cells were infected at 60 PFU/well with
either TB40-BAC4 or Merlin and incubated for 21 days in the presence of
seronegative or seropositive sera (1:50). Cells were imaged after ﬁxing and
staining for IE-1. (B, C) ARPE-19 cells were infected with either TB40-BAC4
(B) or Merlin (C) and incubated for 21 days in the presence of Cytotect
(purple) or seronegative (white) or seropositive (black) sera (1:50). Plaque
size was measured after ﬁxing and staining for IE-1. (D) ARPE-19 cells were
infected with 60 PFU/well of either TB40-BAC4, Merlin or Merlin-UL128G>T
and incubated for 21 days in the presence of the indicated concentrations of
Cytotect. Plaque size was measured after ﬁxing and staining for IE-1. Percent
inhibition was calculated relative to the negative control (no Cytotect). (E)
Cell-free Merlin, Merlin-UL128G>T or TB40-BAC4 were incubated with the
indicated concentrations of Cytotect for 30 min. ARPE-19 cells were then
infected for 2 h and incubated for a further 24 h. Infected cells were counted
after ﬁxing and staining for IE-1. Percent neutralization was calculated rela-
tive to the negative control (no Cytotect). (F) The concentration of Cytotect
that inhibited plaque formation or cell-free infection by 50% was calculated
frompanels D and E. (G)Cell-freeMerlin,Merlin-UL128G>T or TB40-BAC4were
incubated with the indicated concentrations of Cytotect for 30 min. HFFFs
were then infected for 2 h and incubated for a further 24 h. Infected cells
were counted after ﬁxing and staining for IE-1. Percent neutralization was
calculated relative to the negative control (no Cytotect). Error bars represent
SEM.
novo expression of the IE-2-GFP fusion protein (Supplemental
Fig. 1C). In addition, virus was readily transferred back to HFFFs
in co-cultures with flow-purified DCs (Supplemental Fig. 1D).
Fig. 4. Cell-cell spread in Langerhans cells is highly efﬁcient and resistant
to IFNα. (A) Immature DCs or LCs were incubated for 24 h with cell-free
preparations of TB40-BAC4 or Merlin. The percentage of infected cells was
calculated by microscopy after staining with a mouse anti-IE-1 antibody and
DAPI. (B) DCs or LCs were incubated for 4 h or 48 h at a 1:1 ratio with Merlin-
GFP-infected HFFFs (MOI = 5; 72 h post-infection) or cell-free Merlin-GFP.
Non-adherent cells were then removed and incubated alone prior to ﬂow
cytometric analysis 72 h after the start of co-culture or cell-free infection. (C)
DCs or LCs were cultured for 24 h in the presence or absence of IFNα, then
incubated for 4 h or 48 h with Merlin-GFP-infected HFFFs (MOI = 5; 72 h post-
infection) or cell-freeMerlin-GFP. Non-adherent cells were then removed and
incubated alone prior to ﬂow cytometric analysis 72 h after the start of co-
culture or cell-free infection. Assays were performed in quadruplicate. ** P
< 0.01, **** P < 0.0001 (ANOVA). Error bars represent SEM.
Collectively, these data show that UL128L expression corre-
lates with cell association during the replicative cycle of a HCMV
isolate containing a clinical genome, and facilitates efficient cell-
cell transmission into epithelial and myeloid cells.
Cell-cell spread is resistant to neutralizing antibodies
Many current vaccine strategies are designed to induce a
neutralizing antibody response (21-27). However, it is unclear
whether the transmission of HCMV is sensitive or resistant to
neutralization, potentially becausemany studies have used viruses
that spread efficiently via the cell-free route (19, 28-36). To deter-
mine the neutralization sensitivity of Merlin, we tested a panel of
antibody preparations. Cell-free infection of HFFFs and ARPE-
19 epithelial cells was inhibited in all cases (Fig.2A,B), while
direct cell-cell transmission intoHFFFs, ARPE-19 epithelial cells
and DCs was largely unaffected (Fig.2C–E).
Cytotect is a clinical grade product containing high neutraliz-
ing antibody titers against HCMV. In a recent clinical trial, this
formulation was used at a concentration of 100 mg/kg (37). Based
on data from other intravenous immunoglobulin preparations,
this could increase serum IgG levels by up to 2 mg/ml (38). To test
the efficiency of cell-cell transfer under clinically relevant con-
ditions, HFFFs, ARPE-19 epithelial cells or DCs were infected
via the cell-cell route in the presence of Cytotect concentrations
as high as 10mg/ml (Fig. 2F). Cell-cell transfer into ARPE-19
epithelial cells and DCs was inhibited by 50% at concentrations
of 6–8mg/ml, while cell-cell transfer into HFFFs was inhibited
by < 50% at a concentration of 10 mg/ml. Similarly, only weak
inhibition of cell-cell transfer of virus from flow-purified DCs
back into HFFFs or ARPE-19 epithelial cells was observed at
maximal concentrations of Cytotect (Supplemental Fig. 2); at
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these high concentrations, it is even possible that the effects
observed are non-specific, rather than being due to anti-CMV
antibodies. In contrast, cell-free infection with the same virus was
inhibited by 50% at concentrations < 50 µg/ml (HFFFs and DCs)
or < 15 µg/ml (ARPE-19 epithelial cells) (Fig. 2G,H).
To provide comparisons with cell-free infection, experiments
thus far had been performed with virus lacking RL13. Identical
assays were therefore performed using a virus expressing the
complete wt-HCMV proteome (Merlin-RL13+). No consistent
differences in the efficiency of cell-cell transfer were observed be-
tween Merlin and Merlin-RL13+, and both viruses were equally
resistant to the inhibitory effects of Cytotect (Supplement Fig.3).
Thus, cell-cell spread of Merlin is only inhibited at extremely
high antibody concentrations, while cell-free infection is > 400-
fold more susceptible to neutralization.
Resistance to neutralizing antibodies is dependent on high
levels of the pentameric complex
Our findings that cell-cell spread into epithelial cells is resis-
tant to neutralising antibodies is in direct contrast with a large
number of studies in which focus formation in epithelial cells
was found to be highly sensitive to neutralizing antibodies (28,
30, 32-34, 39). To resolve this discrepancy, we performed focus
expansion assays using the TB40-BAC4 strain of HCMV. TB40-
BAC4 is exceptional in retaining the capacity to infect endothe-
lial, epithelial and myeloid cells following in vitro culture, and has
been widely used for these types of study. Focal spread of TB40-
BAC4 was highly sensitive to neutralization (Fig. 3A,B), while
minimal inhibition was observed in parallel assays with Merlin
(Fig. 3A,C). These findings were confirmed in similar experi-
ments with higher concentrations of Cytotect, which revealed that
Merlin was almost 600-foldmore resistant to inhibition compared
with TB40-BAC (Fig. 3D).
In common with most passaged strains of HCMV, TB40-
BAC4 produces high titers of cell-free virus and incorporates
reduced levels of gpUL128–131A in the virion, a characteristic
partially endowed by a G>T nucleotide substitution in one of the
UL128 introns (19). Mutation of the same nucleotide in the Mer-
lin strain (Merlin-UL128G>T) reduces both cell-associated and
virion-associated expression of the UL128 protein, such that it
is intermediate between TB40-BAC4 and Merlin (Supplemental
Fig. 4)(19). In line with UL128 expression levels, focal spread
of Merlin-UL128G>T displayed an intermediate susceptibility to
inhibition compared with Merlin and TB40-BAC4 (Fig. 3D).
The same phenomenon was observed in assays with cell-free
viruses (Fig. 3E), although the differences between strains were
less pronounced (Fig. 3F). In contrast, this pattern was reversed
in cell-free neutralization studies with HFFFs (Fig. 3G). These
differences presumably reflect the fact that entry into fibroblasts
is dependent on the gH/gL/gO complex. Viruses with reduced
levels of gpUL128–131A (19) typically express greater amounts
of gH/gL/gO (40) because gO and gpUL128–131A compete for
binding to gL (41).
Thus, efficient expression of gpUL128–131A, a feature
unique to strains containing a clinical genome (19), renders cell-
cell spread highly resistant to humoral immunity, and cell-free
entry partially resistant to antibodies that neutralise epithelial cell
entry.
Cell-cell spread is resistant to intrinsic LC restriction factors
In further experiments, we investigated whether cell-cell
transfer might differ in other ways from cell-free transmis-
sion. Langerhans cells (LCs) are specialized tissue-resident DCs
thought to play a key role in the early stages of natural infection
with HCMV (42). In vitro, immature DCs are readily infected via
the cell-free route, whereas immature LCs are not (43, 44). This
dichotomy was recapitulated with Merlin (Fig. 4A). In contrast,
much greater numbers of immature LCs were infected via the
cell-cell route over an equivalent period of time (Fig. 4B). Similar
patterns were observed, but with even higher infection frequen-
cies, in longer term assays. Thus, not only were LCs more readily
infectedwhen using the cell-cell route, but the absolute number of
infected cells that it was possible to achieve using cell-cell spread
was much higher than that achieved by cell-free spread.
To ensure these differences were not dependent on the
infected-cell secretome, we repeated the co-culture experiment
with a transwell between TB40-BAC4-infected HFFFs and unin-
fected DCs or LCs (Supplemental Fig. 5A). Alternatively, DCs
or LCs were removed from the transwell after incubation for 72
h over Merlin-infected HFFFs and exposed to cell-free Merlin
(Supplemental Fig. 5B). In both cases, LCs remained significantly
more resistant to infection compared with DCs.
Immature LCs are therefore significantly more susceptible to
cell-cell infection relative to cell-free infection, consistent with
greater intrinsic restriction of the free virion life cycle.
Cell-cell spread is resistant to interferon-induced antiviral
factors
To extend this line of inquiry, we investigated the antiviral
effect of interferon (IFN)α. In these experiments, DCs or LCs
were treated with IFNα, then infected either via co-culture or
by exposure to cell-free virus (Fig. 4C). Cell-free infection of
both DCs and LCs was abrogated in the presence of IFNα. Com-
parable results were obtained with virus infections performed
with transwell membranes placed between infected HFFFs and
uninfectedDCs or LCs, indicating that these differences were not
due to exposure to the infected cell secretome (Supplemental Fig.
5C). In contrast, cell-cell transmission was inhibited only mod-
erately by IFNα, even after 48 h. Similarly, cell-free infection of
HFFFs was suppressed by IFNα, while cell-cell transfer between
HFFFs (Supplemental Fig 5D), or from Merlin-infected DCs or
LCs into uninfectedHFFFs or ARPE-19 cells (Supplemental Fig.
5E) was only minimally affected by IFNα.
Accordingly, cell-cell transfer is more resistant to innate im-
munity compared with cell-free entry across a range of cell types.
It is also notable that RL13 expression did not influence the
susceptibility of this process to the antiviral effects of IFNα or
the intrinsic restrictive properties of LCs (Supplemental Fig. 5F).
In sum, the findings reported here demonstrate that virus
expressing the complete HCMV proteome spreads efficiently via
the cell-cell route, a mode of propagation that confers resistance
to multiple arms of the immune system.
DISCUSSION
The data presented here show that a genetically defined and
clinically relevant strain of HCMV can infect a wide range of cell
types via a process of direct transfer that differs qualitatively from
cell-free entry and likely predominates in vivo. Previous studies
have been limited to strains capable of cell-free transmission,
such as FIX and TB40-BAC4, which incorporate mutations that
reduce expression of the pentameric glycoprotein complex (19).
However, clinical isolates are almost entirely cell-associated in
vitro (18, 45), and the majority of virus is cell-associated in vivo
(17). Moreover, cell-cell spread is essential for viral replication in
animalmodels of CMV infection (46). Despite these fundamental
observations, remarkably little is known about the physiological
mechanism of cell-cell transfer. It is established that soluble
proteins can be transmitted between infected cells (47), and
that small fusion events can occur between infected endothe-
lial cells and polymorphonuclear leukocytes (48). In addition,
virus lacking UL99, an essential tegument protein required for
free virion formation, can still spread via the cell-cell route in
fibroblasts (49). Nonetheless, polymorphonuclear leukocytes are
not productively infected, and virus lacking UL99 spreads very
inefficiently compared with wt-HCMV. These studies also relied
on virus strains that do not express the complete wt-HCMV
proteome (1, 14, 16, 19). In contrast, our experiments with fully
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reconstituted strain Merlin allowed us to demonstrate that high
levels of gpUL128–131A drive efficient cell-cell transmission and
confer resistance to innate and adaptive immune defences.
These results will need to be validated using other strains of
HCMV, since it is possible that there is strain-strain variation
(32). This will require the construction of additional BACs con-
taining genomes that match original clinical isolates, and contain
tet operators upstream of UL128L and RL13 (14). Nonetheless,
it seems likely that the pentameric complex is normally expressed
at high levels in vivo given that clinical isolates grow in a cell-
associated manner akin to Merlin and rapidly acquire similar ab-
lative mutations in UL128L in vitro (1), and that passaged strains
with intact UL128L express lower levels of the protein due to
acquiredmutations (19). It remains unclear whether the observed
effects on cell-cell transfer arise from virion- or cell-associated
membrane expression of the pentameric complex, both of which
are reduced by the G>T mutation used in this work. Previous
studies have shown that HCMV forms syncytia in ARPE-19 and
fibroblast cells, and that this can be inhibited by neutralizing
antibodies (50, 51). These observations suggest a functional role
for membrane-associated glycoproteins. However, relatively few
syncytia were observed with TB40-BAC4, and very few syncytia
were observed with Merlin or the Merlin-UL128G>T mutant.
Cell-cell spread has been particularly well studied in the
context of retroviruses. Akin to HCMV, these viruses propagate
significantly more efficiently via direct transfer compared with
the cell-free route (52-54), and better overcome specific restric-
tion factors and innate immune responses in the process (55-
57). However, these similarities do not necessarily reflect com-
mon mechanisms of viral spread (58, 59). For example, cell-cell
transfer of HIV can be inhibited by many different neutralizing
antibodies (60-62), and although it is more resistant than cell-
free infection with some antibodies (60, 63-67), the differences
are significantly lower than then the 400-fold observed forMerlin;
the resistance of Merlin to all but the highest concentrations
of neutralizing antibodies potentially indicates a qualitatively
distinct mode of transmission. The data presented here also have
substantial implications for the control of HCMV in vivo. During
natural infection, LCs in the oral epithelium are most likely the
first antigen-presenting cells to encounterHCMV(42). Immature
LCs are resistant to infection via the cell-free route (44, 68), and
it has been suggested that this potential bottleneck could feasibly
be exploited to interrupt transmission (42). The propensity of wt-
HCMV to spread via the cell-cell route would undermine any
such efforts. In addition, cell-cell spread enhances the kinetics of
viral infection (52, 69, 70) and enables drug resistance to develop
more quickly in the setting of HIV (71, 72). These phenotypes
can be attributed to the fact that multiple virions are delivered
per cell during a cell-cell transmission event (71, 73). It remains
to be determined whether the same is true for HCMV.
It will be interesting to determine whether antibodies capable
of suppressing cell-cell spread are also effective at neutralising
cell-free virus. Nevertheless, the concentrations of IgG required
to inhibit cell-cell transmission of Merlin may be difficult to
achieve in vivo (38). This observation has profound ramifications
for the development of therapeutic interventions, especially as
current vaccine studies are focused on neutralizing antibodies
(21-27). Several of these antibodies are considerably more potent
than Cytotect when measured using cell-free passaged HCMV
(21, 22, 33), raising the possibility that they could have efficacy
against cell-cell spread of clinical virus. However, until they are
tested against virus expressing the wildtype HCMV proteome, it
is not possible to determine whether potent inhibition of cell-free
infection correlates with inhibition of cell-cell spread, or whether
inhibition of cell-cell spread is simply dependent upon antibody
concentration. These antibodies may of course have efficacy in
vivo by inhibiting initial cell-free infection from body fluids, yet
our data suggests that once an initial infection has occurred, they
may be less effective at preventing intra-host spread. Similarly, in
both congenital infection and transplantation, where virus spread
to the fetus/transplant recipientmay conceivably occur by cell-cell
spread, such antibodies may be less effective. It is notable in this
context that studies of the role of neutralising antibodies in vivo
are somewhat mixed; studies have documented an inverse corre-
lation between neutralization titers and intrauterine transmission
(74-77), and virus-specific antibodies have been shown to confer
a degree of protection in animal models (78, 79) and in a trial
in transplant patients (80). Yet the administration of polyclonal
human IgG containing high titers of neutralizing antibodies failed
to prevent congenital infection in a randomized clinical trial (37),
and although anti-gB antibody titres correlated with protection in
a vaccine study of transplant recipients, neutralising titres did not
(81).
Collectively, our data highlight the importance of testing
genetically defined viruses that accurately represent the causative
agent of disease and provide evidence to suggest that neutralizing
antibodies may only limit intra-host spread if present at very high
concentrations. A successful vaccine may therefore need to also
stimulate cytotoxic responses to eliminate cells that are already
infected with HCMV (82).
MATERIALS AND METHODS
Co-culture
Infected HFFFs were washed prior to co-culture, incubated for 15 min
with 222 ng/ml CellTrace Far Red (DDAO-SE; Invitrogen) in PBS, washed
again and resuspended in regular growth medium. For co-culture with
adherent cells (HFFFs, ARPE-19), infected HFFFs were trypsinized and overlaid
on targets 3–7 days post-infection. For co-culture with non-adherent cells
(DCs or LCs), targets were added directly to infected HFFFs 3–4 days post-
infection. Non-adherent targets were washed off at various time points
during co-culture. In all cases, cells were maintained for 72 h to allow
expression of IE2-GFP. For analysis, cells were harvested (if non-adherent) or
trypsinized (if adherent), stained with Fixable Viability 570 (BD), then either
ﬁxed in 2% paraformaldehyde and acquired using an Accuri C6 cytometer
(BD) or acquired directly without ﬁxation using a FACSAria II cytometer
(BD). Informed consent was obtained from all volunteer blood donors, and
experiments were approved by Cardiff University Research Ethics Committee
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